Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier

Drug Metabolism and Disposition

Volumn 37, Issue 6, 2009, Pages 1251-1258

  Zhao, Rong ^a,c   Raub, Thomas J ^b   Sawada, Geri A ^b   Kasper, Steven C ^b   Bacon, James A ^b   Bridges, Arlene S ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Carrier China R and D Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; BREAST CANCER RESISTANCE PROTEIN; CHRYSIN; CIMETIDINE; DIPYRIDAMOLE; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LSN 335984; LY 2228820; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CELL MEMBRANE PERMEABILITY; CELL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; KNOCKOUT MOUSE; MALE; MONOLAYER CULTURE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUADRUPOLE MASS SPECTROMETRY; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG SYNERGISM; MALE; MICE; MICE, INBRED C57BL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OSMOTIC PRESSURE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS;

MURINAE; MUS;

EID: 66649132535     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025064     Document Type: Article

References (42)

1. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668. (Pubitemid 34020420)
2. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der Valk P, Leenstra S, Baayen JC, et al. (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849-857. (Pubitemid 40847353)
3. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29-45. (Pubitemid 39410561)
4. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchaveleva I, Klein-Szanto A, Gallo JM, et al. (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 67:262-268. (Pubitemid 46142783)
5. Bihorel S, Camenisch G, Lemaire M, and Scherrmann JM (2007) Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood-brain barrier. J Neurochem 102:1749-1757. (Pubitemid 47329285)
6. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
7. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, upregulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301. (Pubitemid 38581436)
8. Cooray HC, Blackmore CG, Maskell L, and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-2063. (Pubitemid 36005925)
9. Dagenais C, Rousselle C, Pollack GM, and Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386. (Pubitemid 30108457)
10. Dallaire L, Tremblay L, and Beliveau R (1991) Purification and characterization of metabolically active capillaries of the blood-brain barrier. Biochem J 276 (Pt 3:745-752.
11. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, and van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440-6449. (Pubitemid 350075034)
12. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95:15665-15670. (Pubitemid 29018757)
13. Enokizono J, Kusuhara H, and Sugiyama Y (2007) Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol 72:967-975. (Pubitemid 47481419)
14. Erdilyi DJ, Kámory E, Csókay B, Andrikovics H, Tordai A, Kiss C, Filni-Semsei A, Janszky I, Zalka A, Fekete G, et al. (2008) Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. Pharmacogenomics J 8:321-327.
15. Hervey PS and Goa KL (1999). Extended-release dipyridamole/aspirin. Drugs 58:469-477. (Pubitemid 29427857)
16. Ho NFH, Raub TJ, Burton PS, Barsuhn CL, Adson A, Audus KL, and Borchardt RT (2000) Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers, in Transport Processes in Pharmaceutical Systems (Gordon GL, Lee IP, and Topp EM eds) pp 219-316, Marcel Dekker, New York.
17. Hough LB, Glick SD, and Su K (1986) Cimetidine penetrates brain and inhibits non-opiate footshock-induced analgesia. Pharmacol Biochem Behav 24:1257-1261. (Pubitemid 16067407)
18. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129. (Pubitemid 40321346)
19. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
20. Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, and Bendayan R (2007) Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm Res 24:1262-1274. (Pubitemid 46870591)
21. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, and Sugiyama Y (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:44-52. (Pubitemid 40096451)
22. Lefranc F, Yeaton P, Brotchi J, and Kiss R (2006) Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). Int J Oncol 28:1021-1030.
23. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621. (Pubitemid 39121487)
24. Mader M, de Dios A, Shih C, Bonjouklian R, Li T, White W, López de Uralde B, Sánchez- Martinez C, del Prado M, Jaramillo C, et al. (2008) Imidazolyl benzimidazoles and imidazo[ 4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett 18:179-183.
25. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, and Schinkel AH (2005) Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 67:1765-1771. (Pubitemid 40594178)
26. Orlowski M and Meister A (1965) Isolation of γ-glutamyl transpeptidase from hog kidney. J Biol Chem 240:338-347.
27. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14. (Pubitemid 40128022)
28. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152. (Pubitemid 40096463)
29. Pfister JR, Makra F, and Muehldorf AV (1995) Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents. Bioorg Med Chem Lett 5:2473-2476.
30. Potschka H, Fedrowitz M, and LöscherW(2003) Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306:124-131.
31. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179-194. (Pubitemid 29121971)
32. Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, Cygalova L, Nachtigal P, and Fendrich Z (2006) Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 319:53-62. (Pubitemid 44455110)
33. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, and Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213. (Pubitemid 46956363)
34. Takasato Y, Rapoport SI, and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493. (Pubitemid 14047362)
35. Tanaka Y, Slitt AL, Leazer TM, Maher JM, and Klaassen CD (2005) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326:181-187.
36. Xia CQ, Liu N, Miwa GT, and Gan LS (2007) Interactions of cyclosporin A with breast cancer resistance protein. Drug Metab Dispos 35:576-582. (Pubitemid 46513259)
37. 11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology 33:259-269.
38. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, and Abbott NJ (2004) Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 36:592-604. (Pubitemid 38230176)
39. Yousif S, Marie-Claire C, Roux F, Scherrmann JM, and Declèves X (2007) Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 1134:1-11. (Pubitemid 46156932)
40. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133. (Pubitemid 44771928)
41. Zhang S, Wang X, Sagawa K, and Morris ME (2005a) Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b-/- mice. Drug Metab Dispos 33:341-348. (Pubitemid 40279933)
42. Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, and Mao Q (2005b) BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22:2023-2034. (Pubitemid 41821581)